Ocular Therapeutix (OCUL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.35
- Estimate
- -$0.39
- Surprise
- +9.4%
- Revenue (period 2026-06-30)
- $13.5M
- Score today
- 3.3/10
Revenue source: xbrl.
How the report landed
Ocular Therapeutix (OCUL) reported a narrower loss than forecast — adjusted EPS of -$0.35 against the -$0.39 estimate (a 9.4% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates OCUL Sell at 3.3/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +9.4% surprise compares with a -3.5% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Product: DEXTENZA
- Concentration risk — Pipeline: AXPAXLI
- DATA_ISSUE: analyst_target_implausible (raw $26.00 vs price $7.38 — ratio 3.5×). Rejected, falling back to technical TP.
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.38
- Price target
- $10.40
- Stop
- $6.86
- Upside to target
- +40.9%
Risk check: RSI 25 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-16 — shown for context, not personalized investment advice.
OCUL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.62B
- P/E (fwd)
- -5.0
- 52-week range
- $6.23–$16.44
- Off 52-week high
- 55.1%
- RSI (14)
- 25
- Volume vs avg
- 0.82×
- Score today
- 3.3/10